Obinutuzumab

CHICAGO – In this Healio video exclusive, Christopher Flowers, MD, discusses how the combination of zanubrutinib and obinutuzumab vs. obinutuzumab alone leads to longer PFS in patients with relapsed/refractory follicular lymphoma.

In this video, Michael Choi, MD, discusses the results of the phase 3 Alliance study, pertaining to chronic lymphocytic leukemia, presented at ASCO Annual Meeting.

CHICAGO — The addition of venetoclax to ibrutinib and obinutuzumab did not extend PFS among older patients with treatment-naive chronic lymphocytic leukemia during the COVID-19 pandemic, according to data presented at ASCO Annual Meeting.

Time-limited venetoclax, obinutuzumab and ibrutinib or venetoclax plus obinutuzumab prolonged PFS compared with chemoimmunotherapy among fit, previously untreated patients with chronic lymphocytic leukemia, according to study results.

In a video interview with Healio, Matthew S. Davids, MD, MMSc, of Dana-Farber Cancer Institute, discussed the ReVenG trial, which was presented at ASH Annual Meeting and Exposition.

Several emerging therapies for lupus have shown promising results in the past year, with anifrolumab and obinutuzumab potentially attracting FDA attention, according to a speaker at the Basic and Clinical Immunology for the Busy Clinician symposium.

A recent study showed that a healthy diet may reduce the risk for prostate cancer. It was the top story in hematology/oncology last week.

A combination of obinutuzumab, ibrutinib and venetoclax induced deep remissions in patients with treatment-naive or relapsed/refractory chronic lymphocytic leukemia, according to study results published in Journal of Clinical Oncology.

Healio spoke with Shazia K. Nakhoda, MD, about the importance of collaborative care in the management of patients with CLL.

Healio spoke with Shazia K. Nakhoda, MD, about CLL highlights from recent conferences.